Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with all data for entry = 11205
TargetProtein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557564(US11358948, Compound I-2 | US11623932, Compound 2 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a serial 3-fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557425(US11358948, Compound I-1 | US11623932, Compound 1 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from the commerc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetProtein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557425(US11358948, Compound I-1 | US11623932, Compound 1 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a serial 3-fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557564(US11358948, Compound I-2 | US11623932, Compound 2 ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from the commerc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+3nMAssay Description:Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from the commerc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetProtein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557620(US11358948, Compound I-29 | US11623932, Compound 2...)
Affinity DataIC50: 5.50E+4nMAssay Description:Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a serial 3-fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetDNA damage-binding protein 1/Protein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557573(US11358948, Compound I-3 | US11623932, Compound 3)
Affinity DataIC50: 5.50E+4nMAssay Description:Equal volumes of His-tagged CRBN-DDB1 complex (56 nM) was mixed with Eu-cryptate labeled Anti-6HIS-monoclonal antibody (50× dilution from the commerc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetProtein cereblon(Human)
Kymera Therapeutics

US Patent
LigandPNGBDBM557573(US11358948, Compound I-3 | US11623932, Compound 3)
Affinity DataIC50: 1.00E+5nMAssay Description:Untagged CRBN-DDB1 complex (final 50 nM) was mixed with Cy5-labeled thalidomide (final 20 nM) and various concentrations of compounds (a serial 3-fol...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent